Immunological and virological predictors of outcome during interferon-α therapy of chronic hepatitis C

Journal of Viral Hepatitis

Volumn 7, Issue 1, 2000, Pages 64-74

  Saito, Hidetsugu ^a   Ebinuma, H ^a   Satoh, I ^b   Miyaguchi, S ^c   Tada, S ^d   Iwabuchi, N ^e   Kumagai, N ^e   Tsuchimoto, K ^e   Morizane, T ^f   Ishii, H ^a  

^a KEIO UNIVERSITY   (Japan)

^b Nerima General Hospital   (Japan)

^c Tokyo Metropolitan Ohtsuka Hospital ^*  (Japan)

^d NASU RED CROSS HOSPITAL   (Japan)

^e KITASATO INSTITUTE HOSPITAL   (Japan)

^f KANAGAWA DENTAL COLLEGE   (Japan)

Author keywords

Chronic hepatitis C; HCV RNA negativity at 2 days; Interferon; Lymphocyte subpopulation; Response to therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; CD11 ANTIGEN; CD8 ANTIGEN; HLA DR ANTIGEN; RECOMBINANT ALPHA2A INTERFERON; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PERIPHERAL LYMPHOCYTE; PREDICTION; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; FLOW CYTOMETRY; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0034010610     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2000.00193.x     Document Type: Article

References (43)

1. 1 Davis GL, Balart LA, Schiff ER et al. The Hepatitis International Therapy Group. Treatment of chronic hepatitis C with recombinant Interferon alpha. A multicenter randomized, controlled trial. N Engl J Med 1989; 321: 1501-1506.
2. 2 Bisceglie AM, Martin P, Kassianides C et al. Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506-1510.
3. 3 Kawaga T, Morizane T, Saito H et al. A randomized, controlled trial of weekly administration of lymphoblastoid interferon in patients with chronic hepatitis C. J Hepatol 1993; 17: 91-96.
4. 4 Saito H, Ebinuma H, Oda M, Ishii H. Results of the multi-center natural interferon-& treatment for chronic hepatitis C: correlation between total dose, administration periods and efficacy of therapy. Keio J Med 1997; 46: 177-183.
5. 5 Saito H, Ebinuma H, Takahashi M, Atsukawa K, Ohishi T, Ishii H. Short-course of interferon-β for the treatment of chronic hepatitis C: a multicenter trial for evaluating host immunological parameters. Int J Immunother 1998; 14: 115-128.
6. 6 Tsubota A, Chayama K, Ikeda K et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088-1094.
7. 7 Enomoto N, Sakuma I, Asahina Y et al. Mutation in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl Med 1995; 334: 77-81.
8. 8 Kumagai N, Kuramochi S, Toda K et al. Assessment of histological features and outcome of interferon therapy in chronic hepatitis C. J Gastroenterol 1996; 31: 69-74.
9. 9 Kagawa T, Saito H, Tada S, Tsunematsu S, Morizane T, Tsuchiya M. Is hepatitis C virus cytopathic? Lancet 1993; 341: 316-317.
10. 10 Pawlotsky J-M. Hepatitic C virus infection: virus/host interactions. J Viral Hep 1998; 5 (suppl): 3-8.
11. 11 Saito H, Tada S, Ebinuma H et al. Cloning of variable regions of an antibody that reacts with the soluble fraction of human liver cells and its possible value in chronic liver disease. Hepatology 1996; 23: 1498-1506.
12. 12 Li X, Jeffers LJ. Reddy R et al. Immunophenotyping of lymphocytes in liver tissue of patients with chronic liver diseases by flow cytometry. Hepatology 1991; 14: 121-127.
13. 13 Tran A, Yang G, Doglio A et al. Phenotyping of intrahepatic and peripheral blood lymphocytes in patients with chronic hepatitis C. Dig Dis Sci 1997; 42: 2495-2500.
14. 14 Khakoo SI, Soni PN, Savage KA et al. Lymphocyte and macrophage phenotypes in chronic hepatitis C infection. Correlation with disease activity. Am J Pathol 1997; 150: 963-970.
15. 15 Wejstal R, Norkrans G, Lenkei R, Weiland O, Schvarcz R, Fryden A. Peripheral blood lymphocyte subsets in patients with chronic hepatitis C - effects of interferon treatment. Liver 1992; 12: 161-167.
16. 16 Wejstal R, Norkrans G, Weiland O et al. Lymphocyte subsets and β2-microglobulin expression in chronic hepatitis C/non-A, non-B. Effects of interferon-a treatment. Clin Exp Immunol 1992; 87: 340-345.
17. 17 Enomoto N, Sakuma I, Asahina Y et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b: sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995; 96: 224-230.
18. 18 Gale MJ, Korth MJ, Tang NM et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997; 230: 217-227.
19. 19 Okamoto H, Okada S, Sugiyama YA et al. Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5′-noncoding region. Jpn J Exp Med 1990; 60: 215-222.
20. 20 Bianchi L, DeGroote J, Desmet VJ et al. Acute and chronic hepatitis revisited. Review by an international group. Lancet 1977; 2: 914-915.
21. 21 Kato N, Yokosuka O, Hosoda K et al. Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: increase of the virus in advanced liver disease. Hepatology 1993; 18: 16-20.
22. 22 Meyer, zum Büchenfelde KH, Lohse AW et al. The role of autoimmunity in hepatitis C infection. J Hepatol 1995; 22 (suppl): 93-96.
23. 23 Iwata K, Wakita T, Okumura AA et al. Interferon gamma production by peripheral blood lymphocytes to hepatitis C virus core protein in chronic hepatitis C infection. Hepatology 1995; 22: 1057-1064.
24. 24 Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of human leukocyte antigens DR3 and DR4 in chronic viral hepatitis. Dig Dis Sci 1995; 40: 2098-2106.
25. 25 Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Genetic predispositions for the immunological features of chronic active hepatitis. Hepatology 1993; 18: 816-822.
26. 26 Kaneko T, Nakamura I, Kita H, Hiroishi K, Moriyama T, Imawari M. Three new cytotoxic T cell epitopes identified within the hepatitis C virus nucleoprotein. J Gen Virol 1996; 77: 1305-1309.
27. 27 Kita H, Moriyama T, Kaneko T et al. A helper T-cell antigen enhances generation of hepatitis C virus-specific cytotoxic T lymphocytes in vitro. J Med Virol 1995; 45: 386-391.
28. 28 Ballardini G, Groff P, Giostra F et al. Hepatocellular expression of HLA-A, B, C molecules predicts primary response to interferon in patients with chronic hepatitis C. Am J Clin Pathol 1994; 102: 746-751.
29. 29 Jung M-C, Diepolder HM, Pare GR. T cell recognition of hepatitis B and C viral antigens. Eur J Clin Invest 1994; 24: 641-650.
30. 30 Battegay M, Fikes J, Di Bisceglie AM et al. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol 1995; 69: 2462-2470.
31. 31 Vitte RL, Fortier C, Richardet JP et al. HLA antigens in patients with chronic hepatitis C. Tissue Antigens 1995; 45: 356-361.
32. 32 Koziel MJ, Dudley D, Afdhal N et al. HLA-class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. J Clin Invest 1995; 96: 2311-2321.
33. 33 Liaw YF, Lee CS, Tsai SL, et al. T-cell-mediated autologous hepatocytotoxicity in patients with chronic hepatitis C virus infection. Hepatology 1995; 22: 1368-1373.
34. 34 Weiner A, Erickson AL, Kansopon J et al. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci USA 1995; 92: 2755-2759.
35. 35 Miyaguchi S, Saito H, Ebinuma H, Morizane T, Ishii H. Possible association between HLA antigens and the response to Interferon in Japanese patients with chronic hepatitis C. Tissue Antigens 1997; 49: 605-611.
36. 36 Ballardini G, Groff P, Pontisso P et al. Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A, B, C, and intercellular adhesion-1 molecules. J Clin Invest 1995; 95: 2067-2075.
37. 37 Mosnier JF, Scoazec JY, Marcellin P, Degott C, Benhamou JP, Feldmann G. Expression of cytokine-dependent immune adhesion molecules by hepatocytes and bile duct cells in chronic hepatitis C. Gastroenterology 1994; 107: 1457-1468.
38. 38 Nouri-Aria KT, Koskinas J, Tibbs CJ, Portmann BC, Williams R. Serum intercellular adhesion molecule-1 levels in chronic hepatitis C: association with disease activity and response to Interferon α. Gut 1995; 36: 599-603.
39. 39 Saito H, Ebinuma H, Tsuchimoto K et al. High level of P-selectin in patients responded to interferon-α treatment for chronic hepatitis C. Hepatol Res 1998; 10: 225-236.
40. 40 Puppo F, Piccioto A, Brenci S et al. Behavior of soluble HLA class I antigens in patients with chronic hepatitis C during interferon therapy: and early predictor marker of response? J Clin Immunol 1995; 15: 179-184.
41. 41 Tada S, Saito H, Tsunematsu S et al. Interferon regulatory factor-1 gene abnormality and loss of growth inhibitory effect on interferon-α in human hepatoma cell lines. Int J Oncol 1998; 13: 1207-1216.
42. 42 Tanaka E, Kiyosawa K, Matsumoto A et al. Serum levels of hepatitis C virus core protein in patients with chronic hepatitis C treated with interferon alfa. Hepatology 1996; 23: 1330-1333.
43. 43 Saitoh H, Naitoh S, Okamoto H, Akahane Y. Prompt decrease of circulating hepatitis C virus in patients with chronic hepatitis C after treatment with interferon. J Interferon Res 1994; 14: 2 39-244.